- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.
Syncom Formulations reported strong Q1 results: total income rose 8% to ₹133.36 Cr, and PAT surged 58% to ₹24.85 Cr. The Board proposes a ₹0.10 per share final dividend for FY26. Growth is driven by its ethical, prescription-led model and expanding market presence.
Syncom Formulation's Managing Director, Mr. Vijay Shankarlal Bankda, has resigned, effective August 11, 2026. **Issue:** Resignation of a key leadership figure. **Company's Response/Mitigation:** The company states this is part of a deliberate leadership transition and succession planning process, aimed at ensuring stability, continuity, and a smooth handover to incoming leadership....
SYNCOMF announces its Whole-Time Director, Mr. Kedarmal Shankarlal Bankda, has resigned, effective 11th August, 2026. **Issue:** A key leadership change with the departure of a Whole-Time Director. **Possible Impact:** Investors might look for clarity on leadership stability and operational continuity. **Company's Response/Mitigation:** The company states the reasons are "timely succession...